2026-06-01T15:42:27-05:00 2025-09-30 390859910 BAKER TILLY ADVISORY GROUP LP 333 BUSH STREET STE 1000 SAN FRANCISCO CA 94104 990 2024-10-01 770207331 PALO ALTO VETERANS INSTITUTE FOR RESEARCH PALO 6502392800 3801 MIRANDA AVENUE PALO ALTO CA 943040038 ELAINE STAATS CEO 6502392800 2026-06-01 1 1 MICHAEL LUMSDEN P01262236 4159561500 2026-06-01 2024 2025-03-06 01:10:19Z PAVIR ELAINE STAATS MPH 3801 MIRANDA AVENUE PALO ALTO CA 943040038 35854131 0 X WWW.PAVIR.ORG X 1988 CA PAVIR'S MISSION IS TO ADVANCE VETERAN HEALTH AND PUBLIC HEALTH THROUGH INNOVATION RESEARCH. PAVIR WORKS WITH MORE THAN 100 PRINCIPAL INVESTIGATORS, BOTH CLINICIAN SCIENTISTS WHOSE TIME IS DIVIDED BETWEEN PATIENT CARE AND RESEARCH, AND THOSE WHOSE SOLE RESPONSIBILITY IS RESEARCH, AT THE VA PALO ALTO HEALTH CARE SYSTEM (VAPAHCS). THIS VA RESEARCH INCLUDES NOT ONLY CLINICAL RESEARCH, BUT BASIC SCIENCE INVESTIGATING DISEASE MECHANISMS IN THE LABORATORY AS WELL AS DATA DRIVEN HEALTH SERVICES RESEARCH DEVELOPING IMPROVED MODELS OF HEALTH CARE DELIVERY. VA RESEARCH ADDRESSES HEALTH CHALLENGES ESPECIALLY PREVALENT IN VETERANS, INCLUDING POST-TRAUMATIC STRESS DISORDER (PTSD), TRAUMATIC BRAIN INJURY (TBI), GERIATRIC MEDICINE AND POLYTRAUMA AS WELL AS OTHER PUBLIC HEALTH ISSUES. RESEARCHERS HAVE APPOINTMENTS AT VAPAHCS, AND MOST ALSO HOLD FACULTY APPOINTMENTS AT THE STANFORD UNIVERSITY SCHOOL OF MEDICINE. 13 3 203 7 0 0 23286921 25318301 7728039 10144436 602254 367884 29413 23510 31646627 35854131 0 0 0 0 18983304 19815713 0 0 0 15371897 13213675 34355201 33029388 -2708574 2824743 17246189 19146651 12030150 11109618 5216039 8037033 X PAVIR'S MISSION IS ADVANCING VETERANS AND PUBLIC HEALTH THROUGH INNOVATIVE RESEARCH. PAVIR WORKS WITH MORE THAN 100 PRINCIPAL INVESTIGATORS AND 200 RESEARCH STAFF TO SUPPORT BASIC SCIENCE, CLINICAL AND HEALTH SERVICES RESEARCH TO REALIZE ITS MISSION. PAVIR'S DIVERSE STUDIES SPAN THE ENTIRE SPECTRUM OF HEALTH RESEARCH FROM THE INVESTIGATION OF DISEASES IN THE LABORATORY THROUGH TESTING NEW DRUG TREATMENTS AND DEVELOPING IMPROVED MODELS OF HEALTH CARE DELIVERY TO LOOKING AT OUTCOMES BOTH INDIVIDUALLY AND ON A LARGE SCALE. PAVIR'S RESEARCH ADDRESSES HEALTH CHALLENGES THAT HAVE BEEN FACED ESPECIALLY BY VETERANS, INCLUDING POST-TRAUMATIC STRESS DISORDER, TRAUMATIC BRAIN INJURY, GERIATRIC MEDICINE, REHABILITATION, SLEEP AND OTHER VETERANS AND PUBLIC HEALTH ISSUES. PAVIR'S INVESTIGATORS HAVE APPOINTMENTS AT THE VA PALO ALTO HEALTH CARE SYSTEM AND MOST ALSO HOLD APPOINTMENTS AT THE STANFORD UNIVERSITY SCHOOL OF MEDICINE. 0 0 1310697 0 0 CLINICAL TRANSLATION OF ALLOGENEIC REGENERATIVE CELL THERAPY FOR WHITE MATTER STROKE AND VASCULAR DEMENTIA. PRINCIPAL INVESTIGATOR: IRENE LORENZO LLORENTE, PH.D.STROKE IS THE LEADING CAUSE OF ADULT DISABILITY AND THE SECOND LEADING CAUSE OF DEMENTIA. WHITE MATTER STROKE (WMS) CONSTITUTES UP TO 30% OF ALL STROKE SUBTYPES AND IS A DISTINCT PROCESS FROM "LARGE ARTERY STROKE." WMS BEGINS AS SMALL INFARCTS IN DEEP PENETRATING BLOOD VESSELS IN THE BRAIN BUT PROGRESSES, ACCUMULATES, AND EXPANDS FROM PREEXISTING LESIONS INTO ADJACENT WHITE MATTER TO PRODUCE HEMIPARESIS WITH INCOMPLETE RECOVERY, GAIT ABNORMALITIES, COGNITIVE DECLINE, AND EXECUTIVE DYSFUNCTION CHARACTERISTIC OF VASCULAR DEMENTIA (VAD). UNLIKE LARGE ARTERY STROKE, WMS DOES NOT DAMAGE NEURONAL CELL BODIES BUT PRIMARILY AFFECTS AXONAL TRACTS AND GLIAL CELLS. A CELL-BASED THERAPY CAPABLE OF REPLACING LOST GLIA AND INDUCING STRUCTURAL REPAIR IN WMS/VAD HOLDS GREAT PROMISE. WE HAVE DEVELOPED A UNIQUE ALLOGENEIC HUMAN INDUCED PLURIPOTENT STEM CELL (HIPSC)-DERIVED GLIAL ENRICHED PROGENITOR (GEP) CELL THERAPY PRODUCT FOR THE TREATMENT OF WMS AND VAD. PRECLINICAL STUDIES DEMONSTRATE THAT HIPSC-GEPS TRANSPLANTED INTO THE BRAIN AFTER WMS/VAD PROMOTE MOTOR AND COGNITIVE RECOVERY THROUGH MULTIPLE MECHANISMS OF ACTION, INCLUDING AXONAL GROWTH, ASTROCYTIC MODULATION, OLIGODENDROCYTE DIFFERENTIATION, AND REMYELINATION. THIS YEAR, WE ACHIEVED A SUCCESSFUL PRE-IND MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR GEP-101 (HIPSC-GEPS) ON FEBRUARY 26, 2026. THE DISCUSSION, INFORMED BY THE FDA'S PRELIMINARY WRITTEN RESPONSES DATED FEBRUARY 23, 2026, FOCUSED ON FOUR PRIMARY AREAS: (1) SUITABILITY OF THE HIPSC CELL LINE AND DONOR ELIGIBILITY TESTING, (2) ADEQUACY OF THE PROPOSED CLINICAL DELIVERY DEVICE AND ADDITIONAL NONCLINICAL EVALUATION NEEDS, (3) REQUIREMENTS FOR DEVICE COMPATIBILITY TESTING TO ENSURE PRODUCT QUALITY AND DOSE ACCURACY, AND (4) QUALIFICATION OF CERTAIN MANUFACTURING RAW MATERIALS, INCLUDING THE VEEV RNA REPLICON USED DURING CELL REPROGRAMMING. OVERALL, THE FDA AGREED WITH ALL POSITIONS PRESENTED, CLARIFYING EXPECTATIONS FOR MANUFACTURING CONTROLS, DEVICE USE, AND SUPPORTING NONCLINICAL DATA PRIOR TO IND SUBMISSION.FOLLOWING THE PRE-IND MEETING, WE HAVE SUBMITTED A NEW GRANT PROPOSAL TO SECURE THE NEXT ROUND OF FUNDING AND CONTINUE ADVANCING TOWARD IND APPROVAL AND FUTURE CLINICAL TRANSLATION. 1238218 0 0 NOVEL LYMPHOCYTE CHEMOATTRACTANT RECEPTOR AND LIGAND. PRINCIPAL INVESTIGATOR: EUGENE BUTCHER, M.D.WE HAVE IDENTIFIED A NOVEL LYMPHOCYTE CHEMOATTRACTANT RECEPTOR AND ITS CHEMOATTRACTANT LIGAND, SELECTIVELY EXPRESSED IN LUNG, AIRWAYS, UPPER GI TRACT, GENITOURINARY MUCOSAE AND MUCOSA-ASSOCIATED GLANDS INCLUDING THE PANCREAS AND SALIVARY GLANDS. AIM 1: WE WILL MECHANISTICALLY PROBE THE RECEPTOR-LIGAND INTERACTIONS FOCUSING ON THE SPECIFICITY AND SIGNALING PATHWAYS ACTIVATED BY THE NOVEL RECEPTOR AND ITS ROLE AS A LYMPHOCYTE VS MYELOID CELL CHEMOTACTIC RECEPTOR. STRUCTURE-FUNCTION STUDIES WILL IDENTIFY LIGAND DOMAINS FOR RECEPTOR BINDING AND ACTIVATION. AIM 2: WILL DEFINE THE REGULATION OF THE RECEPTOR IN THE MOUSE, AND ITS ROLE IN LYMPHOCYTE POPULATION OF AND HOMING TO NON-LYMPHOID TISSUES DURING HOMEOSTASIS AND IN THE SETTING OF CHRONIC MULTI-ORGAN AUTOIMMUNE INFLAMMATION. THE ROLES OF THE PATHWAY IN IMMUNE CELL DEVELOPMENT WILL BE PROBED IN MIXED BONE MARROW CHIMERAS IN WHICH RECEPTOR-DEFICIENT VS WILD TYPE STEM CELLS COMPETE FOR RECONSTITUTION OF IMMUNE COMPARTMENTS IN LYMPHOID AND NON-LYMPHOID TISSUES. AIM 3: WILL ELUCIDATE THE TISSUE- AND CELL SUBSET-SPECIFIC EXPRESSION OF THE RECEPTOR AND LIGAND IN HUMANS.WHILE MUCH OF AIM 1 HAS BEEN COMPLETED AND PRESENTED IN OUR NATURE PUBLICATION, THIS AIM AS WELL AS THE GRANT AS A WHOLE HAS AS ITS OVERARCHING GOAL TO IDENTIFY AND CHARACTERIZE THE GPCR INTERACTIONS AND FUNCTIONS OF CXCL17. OUR ALPHA FOLD MODELING SUPPORTED OUR INITIAL CHARACTERIZATION OF CXCL17-GPR25 INTERACTION. USING THIS AS A JUMPING OFF POINT, WE ARE ASKING WHETHER IN SILICO MODELING IN SCREENING MODE CAN IDENTIFY THE FUNCTIONAL GPCR LIGANDS OF CXCL17 (AND THUS POTENTIALLY OF OTHER ORPHAN CHEMOKINES). IN HIGH THROUGHPUT SCREENING MODE, WE GENERATED AF2 MODELS OF CXCL17 INTERACTIONS WITH ALL CLASS A GPCRS AND FIND THAT THE HIGHEST SCORING MODELS INCLUDE GPR25 BUT ALSO TWO OTHER RECEPTORS: BDKRB1, THE INFLAMMATION ASSOCIATED BRADYKININ RECEPTOR, AND NTSR2, THE NEUROTENSIN RECEPTOR. OTHER RECEPTORS SHOWED NO OR UNFAVORABLE INTERACTIONS (DEFINED BY AF2 METRICS INCLUDING IPTM ON LIGAND AND RECEPTOR RESIDUES INTERACTING IN THE LIGAND BIND POCKET OF THE GPCR). THESE IN SILICO FINDINGS SUGGEST THE POSSIBILITY OF ADDITIONAL RECEPTORS FOR CXCL17 THAT COULD IMPACT VASCULAR AND NEUROBIOLOGY. A MAJOR FOCUS THIS YEAR IN REGARDS TO AIM 2 HAS BEEN ON EXPANDING AND INITIALLY CHARACTERIZING GPR25 DEFICIENT MICE, TO DEFINE THE ROLE OF GPR25 IN LYMPHOCYTE SUBSET REPRESENTATION AND DISTRIBUTION IN MUCOSAL TISSUES. WE HAVE ESTABLISHED THE COLONY AND HAVE EVALUATED BASAL LYMPHOCYTE SUBSETS IN THE RESTING STATE. THE RESULTS LARGELY PARALLEL THOSE IN CXCL17 DEFICIENT MICE, INDICATING THAT CXCL17 IS LIKELY THE ONLY OR THE PREDOMINANT CHEMOKINE LIGAND FOR GPR25. WE HAVE GENERATED MIXED (WT/KO) BONE MARROW CHIMERAS TO DEFINE THE EFFECT OF GPR25 DEFICIENCY BY EVALUATING KO LYMPHOCYTE REPRESENTATION IN COMPETITION WITH WT CELLS IN THE SAME HOST.FOR AIM 3, WE CONTINUE TO EVALUATE GPR25 EXPRESSION IN HUMAN AND MOUSE DISEASE MODELS (SCRNA SEQ DATA TO DATE FROM PUBLIC RESOURCES). WE ARE INTERESTED IN GWAS ASSOCIATIONS OF GPR25 WITH ARTERIAL STIFFNESS: WE SEE SIGNIFICANT T CELL SUBSET EXPRESSION OF GPR25 IN DATA FROM HUMAN CORONARY ARTERY DISEASE. WE ARE ALSO INTERESTED IN UNDERSTANDING THE GWAS ASSOCIATIONS OF HUMAN BLOOD GPR25 WITH AUTOIMMUNE DISEASES ESPECIALLY IBD: THROUGH COLLABORATION WITH DR. MONTGOMERY, COLOCALIZATION ANALYSIS INDICATE THAT GPR25 HAS THE HIGHEST PP4 AMONG GENES IN THE REGION FOR IBD, CROHN'S DISEASE, AND ULCERATIVE COLITIS, PRIORITIZING GPR25 AS THE LIKELY CAUSAL GENE AT THIS LOCUS. WE HAVE PERFORMED RNA SCOPE ON INTESTINAL SAMPLES FROM IBD PATIENTS (WITH OUR COLLABORATOR AND CO-INVESTIGATOR SERENA TAN) REVEALING STRONG CXCL17 EXPRESSION WITHIN SITES OF PYLORIC METAPLASIA CONSISTENT WITH SINGLE-CELL RNA-SEQ DATA AND SUPPORTING RECRUITMENT OF GPR25 IMMUNE CELLS TO INFLAMED MUCOSA. RECRUITMENT OF GPR25+ TREGS COULD EXPLAIN THE ROLE OF HIGHER PBMC GPR25 IN REDUCING IBD. 1062166 0 0 ALL OF US RESEARCH PROGRAM. PRINCIPAL INVESTIGATORS: PHILIP TSAO, PH.D. THE ALL OF US RESEARCH PROGRAM (ALL OF US) IS A LARGE COLLABORATIVE INITIATIVE SPONSORED BY THE NATIONAL INSTITUTES OF HEALTH (NIH). ALL OF US INCLUDES A CONSORTIUM OF AWARDEES FROM MULTIPLE INSTITUTIONS, INCLUDING THE DEPARTMENT OF VETERANS AFFAIRS. ALL OF US IS WORKING TO IMPROVE HEALTHCARE THROUGH RESEARCH BY BUILDING A DIVERSE DATABASE OF PARTICIPANT SELF-REPORT INFORMATION, BIOSPECIMENS, AND ELECTRONIC HEALTH RECORDS THAT CAN INFORM FUTURE RESEARCH ON A VARIETY OF HEALTH CONDITIONS. VA PARTICIPATION IN ALL OF US IS OVERSEEN BY TWO CO-PIS, LOCATED AT THE VA PALO ALTO HEALTHCARE SYSTEM AND THE VA BOSTON HEALTHCARE SYSTEM. THESE TWO INSTITUTIONS SERVE AS THE COORDINATING CENTERS FOR VA RESPONSIBLE FOR CENTRALIZED RECRUITMENT, ENGAGEMENT CAMPAIGNS, AND COMPLIANCE WITH PROGRAM REQUIREMENTS. 24180777 0 10144436 PAVIR IS PRIVILEGED TO WORK WITH A LARGE COMMUNITY OF UNIQUELY TALENTED MEDICAL RESEARCHERS ACROSS A BROAD SPECTRUM OF RESEARCH AREAS AS WE FULFILL OUR MISSION OF ADVANCING VETERANS AND PUBLIC HEALTH THROUGH INNOVATIVE RESEARCH. THE RANGE OF RESEARCH ACTIVITIES IS BROAD AND INCLUDES SPECIAL EMPHASIS ON MAJOR DISEASE CATEGORIES, ALL OF WHICH ARE PREVALENT IN THE VA'S PATIENT POPULATION. THESE INCLUDE CARDIOVASCULAR MEDICINE, MENTAL HEALTH, CHRONIC INFLAMMATORY DISEASE, STEM CELL/REGENERATIVE MEDICINE, PAIN, SLEEP DISORDERS, AND MANY OTHERS. IN ADDITION TO DISEASE SPECIFIC RESEARCH, PAVIR IS ENGAGED IN SUPPORTING RESEARCH AIMED AT ENHANCING HEALTH CARE. PAVIR'S RESEARCH PORTFOLIO INCLUDES COMPARATIVE STUDIES IN WHICH RESEARCH TEAMS ARE LEARNING WHICH TREATMENTS ARE SUPERIOR TO OTHERS, HOW TO AUGMENT OR IMPROVE STANDARD OF CARE, AS WELL AS HOW TO ENHANCE THE OPERATION OF HEALTH CARE. FURTHERMORE, PAVIR IS SUPPORTING EDUCATIONAL ACTIVITIES, ESPECIALLY IN AREAS OF ADVANCING CLINICAL CARE FOR VETERANS AND FOSTERING THE PROFESSIONAL DEVELOPMENT OF OUR EXPERT STAFF. 24180777 0 10144436 27791858 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 48 0 1 203 1 0 0 0 0 0 0 0 0 0 0 0 0 X 13 3 0 0 0 0 0 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X JENNY DAO 6502392822 3801 MIRANDA AVENUE PALO ALTO CA 94304 ODETTE HARRIS DIRECTOR / BOARD CHAIR 1.00 40.00 X X 0 0 0 PAUL HEIDENREICH DIRECTOR / SECRETARY & TREASURER 0.50 40.00 X X 0 0 0 MAHEEN ADAMSON DIRECTOR 0.50 40.00 X 0 0 0 JON FULLER STATUTORY VA DIRECTOR 0.50 40.00 X 0 0 0 JEAN GURGA STATUTORY VA DIRECTOR 0.50 40.00 X 0 0 0 NGAN HUANG DIRECTOR 0.50 40.00 X 0 0 0 MEGHAN KEMNEC STATUTORY NON-VA DIRECTOR 0.50 0.00 X 0 0 0 MIKE KOZAL STATUTORY VA DIRECTOR (THRU 10/2024) 0.50 40.00 X 0 0 0 WARE KUSCHNER DIRECTOR 0.50 40.00 X 0 0 0 JENNIFER LEE STATUTORY VA DIRECTOR 0.50 40.00 X 0 0 0 LAWRENCE LEUNG DIRECTOR / AUDIT COMMITTEE CHAIR 0.50 40.00 X 0 0 0 PAYAM MASSABAND STATUTORY VA DIRECTOR 0.50 40.00 X 0 0 0 VANESSA RIDLEY DIRECTOR 0.50 0.00 X 0 0 0 ROBERT SLOSS STATUTORY NON-VA DIRECTOR 0.50 0.00 X 0 0 0 ELAINE STAATS CHIEF EXECUTIVE OFFICER 40.00 0.00 X 282965 0 63244 LILY IBRAGIMOV DIRECTOR OF FINANCE & ACCOUNTING 40.00 0.00 X 185095 0 31098 MARY THORNTON DIRECTOR OF OPERATIONS 40.00 0.00 X 194444 0 32397 ALLISON MALATE DIRECTOR OF SPONSORED RESEARCH 40.00 0.00 X 190624 0 31382 LISA CLARK DIRECTOR OF HUMAN RESOURCES 40.00 0.00 X 197306 0 18452 NORA THOMAS HUMAN RESOURCES MANAGER 40.00 0.00 X 151316 0 27396 TIMOTHY MYLES RESEARCH SCIENTIST III 40.00 0.00 X 185636 0 41718 XINGUO JIANG RESEARCH SCIENTIST II 40.00 0.00 X 160856 0 41247 CALVERT LEE SR. CLINICAL RESEARCH MANAGER 40.00 0.00 X 155791 0 41464 STEPHANIE HENSEY DEVELOPER / DATABASE ADMINISTRATOR 40.00 0.00 X 158718 0 26314 JIAN LUO RESEARCH SCIENTIST III 40.00 0.00 X 158648 0 14685 2021399 0 369397 42 0 1 0 0 21268425 4049876 25318301 MEDICAL RESEARCH 541700 5150942 5150942 PERSONNEL REIMBURSEMENTS - VAPAHC 541700 4279767 4279767 GOVERNMENT FEES & CONTRACTS 541700 713727 713727 10144436 367884 367884 MISCELLANEOUS INCOME 900099 23510 23510 23510 35854131 10144436 0 391394 X 1480336 1480336 14241584 11836977 2404607 1008277 826625 181652 1902193 1550405 351788 1183323 912057 271266 40187 25014 15173 75870 75870 5050394 4959741 90653 126145 115281 10864 363888 167300 196588 352491 339328 13163 125574 94449 31125 221702 221702 83527 83527 SUBRECIPIENTS 4387176 4387176 RESEARCH MATERIAL COST 2164917 2164730 187 EQUIPMENT MAINTENANCE 48227 48227 OTHER PERSONNEL COST 18026 18026 155551 142846 12705 33029388 27791858 5237530 0 2531128 3218894 8881528 11100159 3910131 3075804 104137 131161 4166239 3319849 759833 846390 1059432 774243 17246189 19146651 4533705 4202472 7496445 6854597 0 52549 12030150 11109618 X 4883176 8015245 332863 21788 5216039 8037033 17246189 19146651 X 2824743 11777 -15526 X 0 1 X 1 1 1 X VA PALO ALTO HEALTH CARE SYSTEM PALO ALTO CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 4166239 3319849 846390 846390 DUE TO VAPAHCS 52549 52549 X 35850382 11777 -15526 -3749 35854131 0 35854131 33029388 0 33029388 0 33029388 PART X, LINE 2: THE ORGANIZATION OPERATES AS A NONPROFIT ORGANIZATION AND HAS BEEN NOTIFIED BY THE TAXING AUTHORITIES THAT IT IS EXEMPT FROM FEDERAL INCOME AND STATE FRANCHISE TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND SECTION 23701D OF THE REVENUE AND TAXATION CODE OF THE STATE OF CALIFORNIA, RESPECTIVELY. THE ORGANIZATION QUALIFIES FOR THE CHARITABLE CONTRIBUTION DEDUCTION UNDER IRC SECTION 170(B)(1)(A)(III) AND HAS BEEN CLASSIFIED AS AN ORGANIZATION THAT IS NOT A PRIVATE FOUNDATION UNDER SECTION 509(A)(1). THE ORGANIZATION FILES EXEMPT ORGANIZATION RETURNS AND, IF APPLICABLE, UNRELATED BUSINESS INCOME TAX RETURNS IN THE U.S. FEDERAL AND CALIFORNIA JURISDICTIONS. THERE IS NO UNRELATED BUSINESS INCOME TAX FOR THE YEARS ENDED SEPTEMBER 30, 2025 AND 2024. ACCORDINGLY, NO PROVISION FOR INCOME TAXES IS INCLUDED IN THE FINANCIAL STATEMENTS. THE ORGANIZATION HAD NO UNRECOGNIZED TAX BENEFITS AT SEPTEMBER 30, 2025 AND 2024. PART XI, LINE 2D - OTHER ADJUSTMENTS: RETURNED CONTRIBUTIONS -15,526. X X X 0 0 0 0 0 0 0 0 0 ELAINE STAATS CHIEF EXECUTIVE OFFICER 282965 0 0 0 0 0 26526 0 36718 0 346209 0 0 0 TIMOTHY MYLES RESEARCH SCIENTIST III 185636 0 0 0 0 0 5000 0 36718 0 227354 0 0 0 MARY THORNTON DIRECTOR OF OPERATIONS 194444 0 0 0 0 0 17942 0 14455 0 226841 0 0 0 ALLISON MALATE DIRECTOR OF SPONSORED RESEARCH 190624 0 0 0 0 0 17282 0 14100 0 222006 0 0 0 LILY IBRAGIMOV DIRECTOR OF FINANCE & ACCOUNTING 185095 0 0 0 0 0 16606 0 14492 0 216193 0 0 0 LISA CLARK DIRECTOR OF HUMAN RESOURCES 197306 0 0 0 0 0 18062 0 390 0 215758 0 0 0 XINGUO JIANG RESEARCH SCIENTIST II 160856 0 0 0 0 0 15124 0 26123 0 202103 0 0 0 CALVERT LEE SR. CLINICAL RESEARCH MANAGER 155695 0 96 0 0 0 14667 0 26797 0 197255 0 0 0 STEPHANIE HENSEY DEVELOPER / DATABASE ADMINISTRATOR 158718 0 0 0 0 0 14504 0 11810 0 185032 0 0 0 NORA THOMAS HUMAN RESOURCES MANAGER 151316 0 0 0 0 0 14070 0 13326 0 178712 0 0 0 JIAN LUO RESEARCH SCIENTIST III 158648 0 0 0 0 0 14295 0 390 0 173333 0 0 0 FORM 990, PART VII AND SCHEDULE J, PART II: THE ORGANIZATION WROTE TO EACH MEMBER OF THE BOARD OF DIRECTORS WHO WAS COMPENSATED BY THE VA PALO HEALTH CARE SYSTEM REQUESTING PERMISSION TO OBTAIN HIS/HER COMPENSATION INFORMATION FOR THE CALENDAR YEAR ENDED DECEMBER 31, 2024. ALL MEMBERS DECLINED IN WRITING TO PROVIDE THEIR COMPENSATION INFORMATION. NONE OF THE BOARD MEMBERS RECEIVED COMPENSATION IN RELATION TO THEIR DUTIES AS BOARD MEMBERS OF PAVIR. FORM 990, PART VI, SECTION A, LINE 7A PAVIR IS A NONPROFIT CORPORATION AUTHORIZED BY TITLE 38 US CODE SECTIONS 7361 THROUGH 7366 TO BE ESTABLISHED AND AFFILIATED WITH THE DEPARTMENT OF VETERANS AFFAIRS PALO ALTO HEALTH CARE SYSTEM (VAPAHCS). THE REFERENCED STATUTE DICTATES THAT FOUR DIRECTORS SHALL BE THOSE PERSONS HOLDING THE VAPAHCS POSITIONS OF DIRECTOR, CHIEF OF STAFF, ASSOCIATE CHIEF OF STAFF FOR RESEARCH, AND ASSOCIATE CHIEF OF STAFF FOR EDUCATION ("VA STATUTORY DIRECTORS"). FURTHER, ONE OF THE "NON-STATUTORY DIRECTORS" AUTOMATICALLY SHALL BE THE CHAIR OF THE VAPAHCS RESEARCH AND DEVELOPMENT COMMITTEE BY VIRTUE OF HIS OR HER POSITION AS COMMITTEE CHAIR AND ANOTHER "NON-STATUTORY DIRECTOR" SHALL AUTOMATICALLY BE THE CHAIR OF THE ADVISORY RESEARCH COMMITTEE BY VIRTUE OF HIS OR HER POSITION AS COMMITTEE CHAIR. FORM 990, PART VI, SECTION A, LINE 7B THE U.S. DEPARTMENT OF VETERANS AFFAIRS HAS THE AUTHORITY TO IMPOSE REQUIREMENTS AND RESTRICTIONS ON THE ORGANIZATION UNDER TITLE 38 US CODE SECTIONS 7361 THROUGH 7366. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY AN INDEPENDENT TAX ACCOUNTANT IN CONJUNCTION WITH THE ORGANIZATION'S ACCOUNTING AND FINANCE DEPARTMENT AND REVIEWED BY MANAGEMENT; ADJUSTMENTS ARE MADE, AS NECESSARY. A COMPLETE COPY OF THE FORM 990 IS THEN PROVIDED TO ALL VOTING MEMBERS OF THE GOVERNING BODY PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION HAS A CONFLICT OF INTEREST POLICY WHICH COVERS EACH VOTING MEMBER OF THE GOVERNING BODY, OFFICER, AND KEY EMPLOYEE WHICH REQUIRES SUCH INDIVIDUALS TO COMPLETE A "DISCLOSURE QUESTIONNAIRE AND AFFIRMATION OF COMPLIANCE" UPON INITIATING THEIR ASSOCIATION WITH PAVIR AS WELL AS ANY TIME A CHANGE IN THEIR CIRCUMSTANCES MAY RESULT IN A POTENTIAL CONFLICT OF INTEREST OR ANNUALLY (WHICHEVER OCCURS FIRST); THESE QUESTIONNAIRES ARE SUBMITTED TO THE CHIEF EXECUTIVE OFFICER AND PROVIDED TO THE BOARD WILL REVIEW. THE BOARD THEN DECIDES WHETHER ANY DISCLOSURES REPRESENT ACTUAL, PERCEIVED, OR POTENTIAL CONFLICTS OF INTEREST. DISINTERESTED MEMBERS OF THE BOARD VOTE ON THE PROPOSED TRANSACTION OR ARRANGEMENT WHICH MIGHT GIVE RISE TO A CONFLICT; ANY CONFLICTED INDIVIDUAL DOES NOT ANTICIPATE IN ANY IN, OR BE PRESENT DURING, THE DELIBERATIONS AND DECISION-MAKING VOTE OF PAVIR WITH RESPECT TO SUCH MATTER. FORM 990, PART VI, SECTION B, LINE 15 ANNUALLY, PAVIR COLLECTS AND ANALYZES MARKET, SALARY SURVEY AND COMPENSATION STUDY DATA BASED ON COMPARABLE INDUSTRY AND REVENUE. THE BOARD'S COMPENSATION COMMITTEE REVIEWS THE DATA, TAKING INTO ACCOUNT PERFORMANCE AND ACCOMPLISHMENTS WHEN ESTABLISHING THE CEO'S COMPENSATION. THE COMPENSATION COMMITTEE KEEPS MINUTES OF ITS MEETINGS AND REPORTS ITS ACTIONS TO THE FULL BOARD. KEY EMPLOYEES' SALARIES ARE SET BY THE CEO UTILIZING INFORMATION FROM PAVIR'S ANNUAL SALARY SCHEDULES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE GENERAL PUBLIC UPON REQUEST. ADDITIONALLY, THE MOST RECENT AUDITED FINANCIAL STATEMENTS ARE MADE AVAILABLE ON PAVIR'S WEBSITE. FORM 990, PART IX, LINE 11G OTHER FEES FOR SERVICES: PROGRAM SERVICE EXPENSES 4,959,741. MANAGEMENT AND GENERAL EXPENSES 90,653. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 5,050,394. FORM 990, PART XI, LINE 9: RETURNED CONTRIBUTIONS -15,526. VA PALO ALTO HEALTH CARE SYSTEM 3801 MIRANDA AVE PALO ALTO CA 94304 941179505 TEACHING HOSPITAL, PROVIDING A FULL RANGE OF PATIENT CARE SERVICES CA N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0